Hypertension impairs cerebral blood flow in a mouse model for alzheimer’s disease

Current Alzheimer Research

Volumn 12, Issue 10, 2015, Pages 914-922

  Wiesmann, Maximilian ^a   Capone, Carmen ^a   Zerbi, Valerio ^a   Mellendijk, Laura ^a   Heerschap, Arend ^a   Claassen, Jurgen A H R ^a   Kiliaana, Amanda J ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Radboud University Medical Center ^*

Author keywords

Alzheimer sisease; Angiotensin II; Angiotensin II receptor blockers; Cerebrovascular circulation; Diuretics; Hypertension

Indexed keywords

AMYLOID PRECURSOR PROTEIN; ANGIOTENSIN II; EPROSARTAN; HYDROCHLOROTHIAZIDE; PRESENILIN 1; APP PROTEIN, HUMAN; PSEN1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BRAIN BLOOD FLOW; CONTROLLED STUDY; DRUG EFFICACY; DRUG INFUSION; HIPPOCAMPUS; HUMAN; HYPERTENSION; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; PATHOPHYSIOLOGY; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; THALAMUS; WILD TYPE; ANIMAL; BLOOD PRESSURE; BRAIN CIRCULATION; BRAIN CORTEX; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GENETICS; MALE; METABOLISM; PHYSIOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; CEREBRAL CORTEX; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; HUMANS; HYPERTENSION; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; PRESENILIN-1; THALAMUS;

EID: 84959568219     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205012666151027130135     Document Type: Article

References (89)

1. Wimo A, Winblad B, Jonsson L. The worldwide societal costs of dementia: estimates for 2009. Alzheimers Dement 6(2): 98-103 (2010).
2. Arevalo-Rodriguez I, Pedraza OL, Rodriguez A, Sanchez E, Gich I, Sola I, et al. Alzheimer's disease dementia guidelines for diagnostic testing: a systematic review. Am J Alzheimers Dis Other Demen 28(2): 111-9 (2013).
3. Morris JC. The nosology of dementia. Neurol Clin 18: 773-88 (2000).
4. Iadecola C, Gorelick PB. Converging pathogenic mechanisms in vascular and neurodegenerative dementia. Stroke 34: 335-37 (2003)
5. Kilander L, Andren B, Nyman H, Lind L, Boberg M, Lithell H. Atrial fibrillation is an independent determinant of low cognitive function. Stroke 29: 1816-20 (1998)
6. Kivipelto M, Helkala E-L, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322: 1447-51 (2001)
7. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, et al. Midlife blood pressure and dementia: the Honolulu–Asia aging study. Neurobiol Aging 21: 49-55 (2000)
8. Nagata KEN, Sato M, Satoh Y, Watahiki Y, Kondoh Y, Sugawara M, et al. Hemodynamic Aspects of Alzheimer's Disease. Ann N Y Acad Sci 977: 391-402 (2002)
9. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MMB. Association of diabetes mellitus and dementia: the rotterdam study. Diabetologia 39: 1392-97 (1996)
10. Posner HB, Tang M-X, Luchsinger J, Lantigua R, Stern Y, Mayeux R. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology 58: 1175-81 (2000)
11. Ringman JM, Sachs MC, Zhou Y, Monsell SE, Saver JL, Vinters HV. Clinical predictors of severe cerebral amyloid angiopathy and influence of apoe genotype in persons with pathologically verified alzheimer disease. JAMA Neurol 71(7): 878-83 (2014)
12. Elias MF, Wolf PA, D'Agostino RB, Cobb J, White LR. Untreated blood pressure level is inversely related to cognitive functioning: the framingham study. Am J Epidemiol 138: 353-64 (1993)
13. Hofman A, Ott A, Breteler MMB, Bots ML, Slooter AJC, van Harskamp F, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 349: 151-54 (1997)
14. Kilander L, Nyman H, Boberg M, Hansson L, Lithell H. Hypertension is related to cognitive impairment. Hypertension 31: 780-86 (1998)
15. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA 274: 1846-51 (1995)
16. Ruitenberg A, Skoog I, Ott A, Aevarsson O, Witteman JCM, Lernfelt B, et al. Blood pressure and risk of dementia: results from the rotterdam study and the gothenburg H-70 study. Dement Geriatr Cogn Disord 12: 33-39 (2001)
17. Sharp SI, Aarsland D, Day S, Sønnesyn H, Alzheimer's Society Vascular Dementia Systematic Review G, Ballard C. Hypertension is a potential risk factor for vascular dementia: systematic review. Int J Geriatr Psychiatry 26: 661-69 (2011)
18. Skoog I, Gustafson D. Update on hypertension and Alzheimer's disease. Neurol Res 28: 605-11 (2006)
19. Skoog I, Nilsson L, Persson G, Lernfelt B, Landahl S, Palmertz B, et al. 15-year longitudinal study of blood pressure and dementia. Lancet 347: 1141-45 (1996)
20. Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population. Neurology 45: 1161-68 (1995)
21. Haag M, Hofman A, Koudstaal P, Breteler M, Stricker B. Duration of antihypertensive drug use and risk of dementia A prospective cohort study. Neurology 72(20): 1727-34 (2009)
22. Keeman J, Mazel J, Zitman F. Het medisch jaar 2008/2009. Bohn Stafleu van Loghum (2009)
23. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM. Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis 26(4): 699-708 (2011)
24. Marpillat NL, Macquin-Mavier I, Tropeano A-I, Bachoud-Levi AC, Maison P. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens 31(6): 1073-82 (2013)
25. Hanon O, Forette F. Prevention of dementia: lessons from SYSTEUR and PROGRESS. J Neurol Sci 226(1–2): 71-74 (2004)
26. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21(5): 875-86 (2003)
27. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the systolic hypertension in the elderly program (SHEP). JAMA 265(24): 3255-64 (1991)
28. Forette F, Seux M, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the systolic hypertension in europe (syst-eur) study. Arch Intern Med 162(18): 2046-52 (2002)
29. Forette F, Seux M-L, Staessen JA, Thijs L, Birkenhager WH, Babarskiene M-R, et al. Prevention of dementia in randomised double- blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352(9137): 1347-51 (1998)
30. Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 163(9): 1069-75 (2003)
31. Qiu C, Winblad B, Viitanen M, Fratiglioni L. Pulse pressure and risk of Alzheimer disease in persons aged 75 years and older: a community-based, longitudinal study. Stroke 34: 594-99 (2003)
32. Kehoe PG, Wilcock GK. Is inhibition of the renin–angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol 6(4): 373-78 (2007)
33. Brasier AR, Recinos A, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 22(8): 1257-66 (2002)
34. Kehoe PG, Miners S, Love S. Angiotensins in Alzheimer's disease– friend or foe? Trends Neurosci 32(12): 619-28 (2009)
35. Kim SG. Quantification of relative cerebral blood flow change by flow_sensitive alternating inversion recovery (FAIR) technique: application to functional mapping. Magn Reson Med 34(3): 293-301 (1995)
36. Marchesi C, Paradis P, Schiffrin EL. Role of the renin–angiotensin system in vascular inflammation. Trends Pharmacol Sci 29(7): 367-74 (2008)
37. Gorelick PB, Scuteri A, Black SE, DeCarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia a statement for healthcare professionals from the american heart association/american stroke association. Stroke 42(9): 2672-713 (2011)
38. Kurinami H, Shimamura M, Sato N, Nakagami H, Morishita R. Do angiotensin receptor blockers protect against Alzheimer's disease? Drugs Aging 30(6): 367-72 (2013)
39. Ruitenberg A, den Heijer T, Bakker SLM, van Swieten JC, Koudstaal PJ, Hofman A, et al. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam study. Ann Neurol 57(6): 789-94 (2005)
40. Niwa K, Porter VA, Kazama K, Cornfield D, Carlson GA, Iadecola C. Aβ-peptides enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Circ Physiol 281(6): H2417-H24 (2001)
41. Prohovnik I, Mayeux R, Sackeim HA, Smith G, Stern Y, Alderson PO. Cerebral perfusion as a diagnostic marker of early Alzheimer's disease. Neurology 38(6): 931 (1988)
42. Capone C, Faraco G, Park L, Cao X, Davisson RL, Iadecola C. The cerebrovascular dysfunction induced by slow pressor doses of angiotensin II precedes the development of hypertension. Am J Physiol Heart Circ Physiol 300(1): H397-407 (2011)
43. Yamada K, Uchida S, Takahashi S, Takayama M, Nagata Y, Suzuki N, et al. Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer's disease. Brain Res 1352: 176-86 (2010)
44. Muller M, van der Graaf Y, Visseren FL, Mali WPTM, Geerlings MI, for the SSG. Hypertension and longitudinal changes in cerebral blood flow: the SMART-MR study. Ann Neurol 71: 825-33 (2012)
45. Tsukuda K, Mogi M, Iwanami J, Min L-J, Sakata A, Jing F, et al. Cognitive deficit in amyloid-β–injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-γ activation. Hypertension 54: 782-87 (2009)
46. Shlyakhto E. Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from > 10 000 patients and review of the literature. Curr Med Res Opin 23: S13-S18 (2007)
47. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, et al. Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase. Hum Mol Genet 13(2): 159-70 (2004)
48. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 17(6): 157-65 (2001)
49. Lee MK, Borchelt DR, Kim G, Thinakaran G, Slunt HH, Ratovitski T, et al. Hyperaccumulation of FAD-linked presenilin 1 variants in vivo. Nat Med 3(7): 756-60 (1997)
50. Capone C, Faraco G, Anrather J, Zhou P, Iadecola C. Cyclooxygenase 1–derived prostaglandin E2 and EP1 receptors are required for the cerebrovascular dysfunction induced by angiotensin II. Hypertension 55(4): 911-17 (2010)
51. Kazama K, Anrather J, Zhou P, Girouard H, Frys K, Milner TA, et al. Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase–derived radicals. Circ Res 95(10): 1019-26 (2004)
52. Kazama K, Wang G, Frys K, Anrather J, Iadecola C. Angiotensin II attenuates functional hyperemia in the mouse somatosensory cortex. Am J Physiol Heart Circ Physiol 285(5): H1890-H99 (2003)
53. Zerbi V, Jansen D, Wiesmann M, Fang X, Broersen LM, Veltien A, et al. Multinutrient diets improve cerebral perfusion and neuroprotection in a murine model of Alzheimer's disease. Neurobiol Aging 35(3): 600-13 (2014)
54. Kim SG. Quantification of relative cerebral blood flow change by flow-sensitive alternating inversion recovery (FAIR) technique: application to functional mapping. Magn Reson Med 34(3): 293- 301 (1995)
55. Kwong KK, Chesler DA, Weisskoff RM, Donahue KM, Davis TL, Ostergaard L, et al. MR perfusion studies with T1-weighted echo planar imaging. Magn Reson Med 34(6): 878-87 (1995)
56. Paxinos G, Franklin KB. The mouse brain in stereotaxic coordinates. USA: Elsevier Academic Press (2008)
57. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 4(8): 487-99 (2005)
58. Shah NS, Vidal J-S, Masaki K, Petrovitch H, Ross GW, Tilley C, et al. Midlife Blood Pressure, Plasma β-Amyloid, and the Risk for Alzheimer Disease: The Honolulu Asia Aging Study. Hypertension 59(4): 780-86 (2012)
59. Paris D, Parker TA, Town T, Suo Z, Fang C, Humphrey J, et al. Role of peroxynitrite in the vasoactive and cytotoxic effects of Alzheimer's beta-amyloid1-40 peptide. Exp Neurol 152(1): 116-22 (1998)
60. Danielyan L, Klein R, Hanson LR, Buadze M, Schwab M, Gleiter CH, et al. Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res 13(2-3): 195-201 (2010)
61. Arendash GW, Su GC, Crawford FC, Bjugstad KB, Mullan M. Intravascular β-amyloid infusion increases blood pressure: implications for a vasoactive role of β-amyloid in the pathogenesis of Alzheimer's disease. Neurosci Lett 268: 17-20 (1999)
62. El Tannir El Tayara N, Delatour B, Volk A, Dhenain M. Detection of vascular alterations by in vivo magnetic resonance angiography and histology in APP/PS1 mouse model of Alzheimer’s disease. MAGMA 23(1): 53-64 (2010)
63. Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C. Alterations in Cerebral Blood Flow and Glucose Utilization in Mice Overexpressing the Amyloid Precursor Protein. Neurobiol Dis 9(1): 61-68 (2002)
64. Niwa K, Kazama K, Younkin L, Younkin SG, Carlson GA, Iadecola C. Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am J Physiol Heart Circ Physiol 283(1): H315-H23 (2002)
65. Meyer EP, Ulmann-Schuler A, Staufenbiel M, Krucker T. Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer's disease. Proc Natl Acad Sci U S A 105(9): 3587-92 (2008)
66. Hawkes CA, Gatherer M, Sharp MM, Dorr A, Yuen HM, Kalaria R, et al. Regional differences in the morphological and functional effects of aging on cerebral basement membranes and perivascular drainage of amyloid-β from the mouse brain. Aging Cell 12(2): 224-36 (2013)
67. Kumar-Singh S, Pirici D, McGowan E, Serneels S, Ceuterick C, Hardy J, et al. Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. Am J Pathol 167(2): 527-43 (2005)
68. Wang Z, Natte R, Berliner JA, van Duinen SG, Vinters HV. Toxicity of Dutch (E22Q) and Flemish (A21G) mutant amyloid β proteins to human cerebral microvessel and aortic smooth muscle cells. Stroke 31(2): 534-38 (2000)
69. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57(2): 178-201 (2008)
70. Hooijmans CR, Van der Zee CEEM, Dederen PJ, Brouwer KM, Reijmer YD, van Groen T, et al. DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice. Neurobiol Dis 33(3): 482-98 (2009)
71. van Groen T, Kiliaan AJ, Kadish I. Deposition of mouse amyloid β in human APP/PS1 double and single AD model transgenic mice. Neurobiol Dis 23(3): 653-62 (2006)
72. Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, et al. Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 117(11): 3393-402 (2007)
73. Savaskan E, Hock C, Olivieri G, Bruttel S, Rosenberg C, Hulette C, et al. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer’s dementia. Neurobiol Aging 22(4): 541-46 (2001)
74. Diener H-C, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol 7(10): 875-84 (2008)
75. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 21(5): 875-86 (2003)
76. Tong XK, Hamel E. Regional cholinergic denervation of cortical microvessels and nitric oxide synthase-containing neurons in Alzheimer's disease. Neuroscience 92(1): 163-75 (1999)
77. Claassen JA, Jansen RW. Cholinergically mediated augmentation of cerebral perfusion in Alzheimer's disease and related cognitive disorders: the cholinergic-vascular hypothesis. J Gerontol A Biol Sci Med Sci 61(3): 267-71 (2006)
78. Hamel E. Perivascular nerves and the regulation of cerebrovascular tone. J Appl Physiol 100(3): 1059-64 (2006)
79. Fujishima M, Ibayashi S, Fujii K, Mori S. Cerebral blood flow and brain function in hypertension. Hypertens Res 18(2): 111-17 (1995)
80. Nobili F, Rodriguez G, Marenco S, De Carli F, Gambaro M, Castello C, et al. Regional cerebral blood flow in chronic hypertension. A correlative study. Stroke 24(8): 1148-53 (1993)
81. Rodriguez G, Arvigo F, Marenco S, Nobili F, Romano P, Sandini G, et al. Regional cerebral blood flow in essential hypertension: data evaluation by a mapping system. Stroke 18(1): 13-20 (1987)
82. Dai W, Lopez OL, Carmichael OT, Becker JT, Kuller LH, Gach HM. Abnormal regional cerebral blood flow in cognitively normal elderly subjects with hypertension. Stroke 39(2): 349-54 (2008)
83. Efimova IY, Efimova NY, Triss SV, Lishmanov YB. Brain perfusion and cognitive function changes in hypertensive patients. Hypertens Res 31(4): 673-78 (2008)
84. Kume K, Hanyu H, Sakurai H, Takada Y, Onuma T, Iwamoto T. Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer's disease. Geriatr Gerontol Int 12(2): 207-14 (2012)
85. Toth P, Tucsek Z, Sosnowska D, Gautam T, Mitschelen M, Tarantini S, et al. Age-related autoregulatory dysfunction and cerebromicrovascular injury in mice with angiotensin II-induced hypertension. J Cereb Blood Flow Metab 33(11): 1732-42 (2013)
86. Carnevale D, Mascio G, D'Andrea I, Fardella V, Bell RD, Branchi I, et al. Hypertension induces brain β-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. Hypertension 60(1): 188-97 (2012)
87. Gentile MT, Poulet R, Pardo AD, Cifelli G, Maffei A, Vecchione C, et al. β-Amyloid deposition in brain is enhanced in mouse models of arterial hypertension. Neurobiol Aging 30(2): 222-28 (2009)
88. Iadecola C, Davisson RL. Hypertension and Cerebrovascular Dysfunction. Cell Metabolism 7(6): 476-84 (2008)
89. Korf ESC, White LR, Scheltens P, Launer LJ. Midlife blood pressure and the risk of hippocampal atrophy: the honolulu asia aging study. Hypertension 44(1): 29-34 (2004).